STUDY SHOWS TUMORICIDAL AND PALLIATIVE BENEFITS OF QUADRAMET

Cytogen presented new data this week relating to its flagship product Quadramet (samarium Sm-153 lexidronam injection). The data were reported by independent investigators who evaluated the use of Quadramet alone and in conjunction with chemotherapy for the treatment of prostate, breast, lung and other cancers.

The authors reported that 89 percent to 93 percent of the patients taking Quadramet experienced either complete or partial relief of pain, while those receiving combination therapy experienced significant improvements on bone scan and in the proportion of patients surviving greater than 18 months.